Literature DB >> 3890130

L-carnitine and haemodialysis: double blind study on muscle function and metabolism and peripheral nerve function.

B Fagher, G Cederblad, M Eriksson, M Monti, U Moritz, P Nilsson-Ehle, H Thysell.   

Abstract

Twenty-eight haemodialysis patients were randomized to L-carnitine, 2 g i.v. three times a week, and saline over a 6-week period. No obvious deficiency of carnitine was found in vastus lateralis with a median value of 12.9 mmol/kg dry weight; range 6.2-21.4. Female patients had lower total plasma carnitine compared to female controls, p less than 0.002, whereas no decrease was found in males. No relationship was found between muscle and total plasma carnitine. After carnitine administration the muscle carnitine level increased about 60%, p less than 0.01, and the total plasma carnitine level more than tenfold, whereas the initially high degree of acylation decreased, p less than 0.02. Maximum dynamic muscular strength was reduced with a mean value of 44% compared with healthy controls. Total metabolic activity of isolated skeletal muscle fibres, measured as heat production with a new technique using a perfusion microcalorimeter, showed a median value of 0.40 mW/g, 25% lower than normal, p less than 0.02. Carnitine administration had no effect on several different tests of muscular function. Neurophysiologically, discrete improvements in the temperature responses were recorded, but no changes in sensory and motor nerve conduction velocities or in vibration thresholds were noted. No symptomatic improvement was observed even in patients with the lowest carnitine levels prior to treatment. Our data do not support the hypothesis that carnitine deficiency contributes to muscle and nerve dysfunction in patients on chronic haemodialysis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3890130     DOI: 10.3109/00365518509160991

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  7 in total

1.  Potential role of carnitine in patients with renal insufficiency.

Authors:  C Wanner; W H Hörl
Journal:  Klin Wochenschr       Date:  1986-07-01

Review 2.  L-Carnitine.

Authors:  J H Walter
Journal:  Arch Dis Child       Date:  1996-06       Impact factor: 3.791

Review 3.  l-Carnitine. A preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism.

Authors:  K L Goa; R N Brogden
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

Review 4.  Mechanisms underlying the anti-wasting effect of L-carnitine supplementation under pathologic conditions: evidence from experimental and clinical studies.

Authors:  Robert Ringseis; Janine Keller; Klaus Eder
Journal:  Eur J Nutr       Date:  2013-03-19       Impact factor: 5.614

5.  Association between carnitine deficiency and the erythropoietin resistance index in patients undergoing peritoneal dialysis: a cross-sectional observational study.

Authors:  Shohei Kaneko; Keiji Hirai; Junki Morino; Saori Minato; Katsunori Yanai; Yuko Mutsuyoshi; Hiroki Ishii; Momoko Matsuyama; Taisuke Kitano; Mitsutoshi Shindo; Akinori Aomatsu; Haruhisa Miyazawa; Yuichiro Ueda; Kiyonori Ito; Susumu Ookawara; Yoshiyuki Morishita
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

Review 6.  Significance of Levocarnitine Treatment in Dialysis Patients.

Authors:  Hiroyuki Takashima; Takashi Maruyama; Masanori Abe
Journal:  Nutrients       Date:  2021-04-07       Impact factor: 5.717

7.  The effects of oral L-carnitine supplementation on physical capacity and lipid metabolism in chronic hemodialysis patients.

Authors:  Yasuo Kudoh; Shinya Aoyama; Takaaki Torii; Qijie Chen; Daigo Nagahara; Hiromi Sakata; Akihiko Nozawa
Journal:  Nephron Extra       Date:  2014-03-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.